Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and clinical settings, as well as in vitro synergism with several anticancer agents. Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5295419/
https://ncbi.nlm.nih.gov/pubmed/27494885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10983
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars